BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
BriaCell's Phase 3 study now has 69 active clinical sites across 15 states, including Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.
'We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell's Phase 2 study,' stated Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer. 'We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families.'
BriaCell's pivotal Phase 3 clinical study is evaluating BriaCell's lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician's choice in advanced metastatic breast cancer (Bria-ABC).
Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary endpoint. BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.
For additional information on BriaCell's pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the Company's beliefs regarding the potential of the Bria-IMT therapy to transform cancer care; the Company's anticipated timeline for analyzing interim data; the Company's analysis of interim data are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@briacell.com
Investor Relations Contact:investors@briacell.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
22 minutes ago
- Medscape
Targeting Macrophages in Peritoneal Colorectal Cancer
This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine from University of Oxford. I'd like to talk today about peritoneal carcinomatosis and some of the underpinning biology that makes this such a dismally prognostic feature of advanced or metastatic colorectal cancer. There's a fantastic group out of the Academic Medical Center in Amsterdam with Louis Vermeulen and his colleague, Dr Grootjans, the group leaders there, who've done some lovely work in dissecting the immune microenvironment of peritoneal deposits. They discovered that peritoneal resident macrophages constitute, or create, a very immunosuppressive environment in metastatic peritoneal colorectal cancer. It's difficult to treat. If we look at response rates to conventional chemotherapy, the response rate is one third in the peritoneum compared to that in the liver or lungs. I've often long considered it a pharmacologic sanctuary site. Perhaps it's to do with drug access, drug distribution, and so on. They've shown, using a mixture of biopsies from patients and in some compelling mouse models, that these resident macrophages play a very important role in suppressing the immune microenvironment. Of course, they've characterized the macrophages very carefully. We can see the immunosuppressive cytokines, like interleukin-10 and VEGF, so that the whole story is very plausible. Equally as important, in a very relevant mouse model of peritoneal metastasis, they showed that this immunosuppressive phenotype can be reversed by using a CSF1 receptor antagonist. This is of interest to me because for a long while, we were interested in a very rare tumor type called tenosynovial giant cell tumor, which can be treated very successfully with CSF1 receptor inhibitors. These drugs exist. They've been approved for the treatment of that very rare macrophage-driven disease, and it looks as if, building on the biology demonstrated by this excellent Amsterdam group, there may be a therapeutic intervention that we could make that's rational and based on depleting these resident macrophages that seem to be the dominant, contributory factor to this rancorous immune microenvironment. This is another opportunity to build on very plausible biology from an outstanding group with drugs that we may already have available. There's a challenge to those who are using the drugs to treat tenosynovial giant cell tumors. Can we actually bring these into the clinic in some way and consider whether we should give the drugs systemically or even locoregionally by giving them intraperitoneally? I think that would be a really interesting experiment to do. Have a look at the paper. There are very clever signs, as you would expect, but think about the potential therapeutic implications. You heard it here first. As always, thanks for listening. I'd be very grateful for any comments or anything you might like to add to this. For the time being, as always, Medscapers, over and out.
Yahoo
an hour ago
- Yahoo
Capella Provides Update on Agreement with Tümad Madencilik
VANCOUVER, BC, July 18, 2025 /CNW/ - Capella Minerals Ltd (TSXV: CMIL) (OTC Pink: CMILF) (FRA: N7D2) ("Capella" or the "Company") is pleased to provide the following update on the Letter of Intent ("LOI") signed by Turkish mining company, Tümad Madencilik Sanayi Ve Ticaret A.S. ("Tümad"), with respect to the staged earn-in proposal for the Company's portfolio of precious and base metal projects in Scandinavia (see Company News Release dated June 2, 2025). Tümad today advised the Company that no material issues have been identified to date and that the Due Diligence process is in its final stages. Both parties are actively working together to move towards closing through the signing of a Definitive Agreement. Tümad currently produces approximately 200,000 ounces of gold per annum from two mining operations located in western Türkiye. This strategic partnership with Capella is expected to provide Tümad with an excellent opportunity to expand its international footprint both within the highly-prospective Scandinavian region and elsewhere. Eric Roth, Capella's President and CEO, commented today: "I am sincerely looking forward to working together with the Tümad team, whose highly respected expertise as mine builders and operators will complement our successful track record in global exploration and discovery. I look forward to ensuring a successful venture going forward for both parties". Private Placement Update The Company wishes to advise that its previously announced private placement of 15,000,000 Units at $0.05 per Unit has been amended to adjust the exercise price of the warrant from $0.10 for two years to and exercise price of $0.075 for a period of two years. The Company feels that this adjustment, while relatively small, will further incentivize and attract investors. All other terms remain the same. Qualified Person and Disclosure Statement The technical information presented in this news release has been prepared in accordance with Canadian regulatory requirements as set out in National Instrument 43-101 ("NI 43-101") and approved by Eric Roth, the Company's President & CEO, a Director, and a Qualified Person under NI 43-101. Mr. Roth holds a Ph.D. in Economic Geology from the University of Western Australia, is a Fellow of the Australian Institute of Mining and Metallurgy (AusIMM) and is a Fellow of the Society of Economic Geologists (SEG). Mr. Roth has over 35 years of experience in international minerals exploration and mining project evaluation. On Behalf of the Board of Capella Minerals Ltd. "Eric Roth" Eric Roth, Ph.D., FAusIMMPresident & CEO About Capella Minerals Ltd Capella is a Canadian exploration and development company with a focus on global gold-copper projects and is currently exploring in the well-endowed Central Lapland Greenstone Belt of northern Finland & in the former copper-cobalt-zinc mining districts of central Norway. In northern Finland, the Company's portfolio consists of 5 copper-gold projects including the priority Killerö E target (a former Anglo American copper-gold project that was never drill tested) and the Saattopora W target (the western extension to Outokumpu Oy's Saattopora former copper-gold mine2) - all of which are located about 40km SW of Agnico Eagle's Kittilä Gold Mine, currently the largest gold producer in Europe. In the Trøndelag Province of central Norway, the Company's focus is on the discovery of high-grade copper-cobalt massive sulfide (VMS) deposits in the former mining districts of Løkken and Røros. The Company's portfolio includes: i) a 100% interest in the advanced exploration-stage Hessjøgruva copper-cobalt project and adjacent Kongensgruve project in the northern Røros mining district, and ii) exposure to the discovery of new satellite copper-cobalt-zinc VMS targets around the past-producing Løkken copper mine through a partnership with Teako Minerals Corp. Capella also holds equity positions in Teako Minerals Corp. and Grit Metals Corp. (formerly European Energy Metals Corp) as a result of the recent divestiture of non-core assets. For additional information you are cordially invited to visit the Capella Minerals Ltd website at or contact Karen Davies, VP Shareholder Relations and Corporate Development, at Tel: +1.604.314.2662 Cautionary Notes and Forward-looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding the future results of operations, performance and achievements of Capella, including the timing, completion of and results from the exploration and drill programs described in this release. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by Capella in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading "Risks and Uncertainties" in Capella's most recently filed MD&A. Capella does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking information. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. SOURCE Capella Minerals Limited View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sable Closes C$1.75 Million Private Placement with Moxico Resources
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 18, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. ('Sable' or the 'Company') (TSXV:SAE | OTCQB:SBLRF) announces that further to the Company's news release of July 2, 2025, it has closed its non-brokered private placement with Moxico Resources plc ('Moxico') raising gross proceeds of C$1,749,000 through the issuance of 31,800,000 common shares ('Shares') at a price of C$0.055 per Share (the 'Private Placement'). As a result of the Private Placement, Moxico owns 31,800,000 Shares, which represent approximately 9.9% of Sable's issued and outstanding Shares. Pursuant to the terms of the subscription agreement entered into by the parties in connection with the Private Placement, Sable granted Moxico customary participation and anti-dilution rights which enable Moxico to maintain its pro rata equity interest in the Company for so long as Moxico maintains a minimum ownership threshold. The proceeds from the Private Placement will be used by the Company for exploration and general corporate and working capital purposes. The Shares issued under the Private Placement are subject to a four month hold period from the date of issue in accordance with applicable securities laws. The Private Placement remains subject to final approval of the TSX Venture Exchange ('TSXV'). The TSXV has conditionally approved the listing of all Shares issued under the Private Placement. Moxico is an unlisted public mining company headquartered in the United Kingdom. As previously announced, the Company and its subsidiary entered into a binding letter agreement with Moxico that granted Moxico an exclusive option to acquire 51% of the Company's El Fierro Project and Cerro-Negro Property, subject to certain exploration and expenditure terms. See the Company's press release dated February 27, 2025 for additional details about Moxico and this option transaction. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. ABOUT SABLE RESOURCES LTD. Sable is a well-funded junior grassroots explorer focused on the discovery of Tier-One new precious metal and copper projects through systematic exploration in endowed terranes located in favorable, established mining jurisdictions. Sable's focus is developing its large portfolio of new Greenfields projects to resource level. Sable is actively exploring the San Juan Regional Program (163,969 ha) incorporating the Don Julio, El Fierro, and Cerro Negro projects in San Juan province, Argentina and the Copper Queen (15,133 ha), Copper Prince (3,980 ha), and Core Mountain (1,925 ha) properties in British Columbia. For further information, please contact: Ruben Padilla, President & CEO at or +1 (520) 488-2520 Related link: Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release. CAUTION REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sable's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Although such statements are based on reasonable assumptions of Sable's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. In particular, this press release contains forward-looking information relating to, among other things, the use of proceed from the Private Placement and the receipt of final approval from the TSXV. While Sable considers these assumptions to be reasonable based on information currently available, they may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined, risks relating to variations in grade or recovery rates, risks relating to changes in mineral prices and the worldwide demand for and supply of minerals, risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, and regulatory risks, including risks relating to the acquisition of the necessary licenses and permits, financing, capitalization and liquidity risks. The forward-looking information contained in this release is made as of the date hereof, and Sable is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained in to access your portfolio
